UA126451C2 - Склади у фіксованих дозах - Google Patents
Склади у фіксованих дозах Download PDFInfo
- Publication number
- UA126451C2 UA126451C2 UAA201911462A UAA201911462A UA126451C2 UA 126451 C2 UA126451 C2 UA 126451C2 UA A201911462 A UAA201911462 A UA A201911462A UA A201911462 A UAA201911462 A UA A201911462A UA 126451 C2 UA126451 C2 UA 126451C2
- Authority
- UA
- Ukraine
- Prior art keywords
- ezetimibe
- bempedoic acid
- tablet
- dissolution
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511889P | 2017-05-26 | 2017-05-26 | |
| US15/859,279 US20180338922A1 (en) | 2017-05-26 | 2017-12-29 | Fixed dose formulations |
| PCT/US2018/034646 WO2018218147A1 (en) | 2017-05-26 | 2018-05-25 | Fixed dose formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA126451C2 true UA126451C2 (uk) | 2022-10-05 |
Family
ID=62621055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201911462A UA126451C2 (uk) | 2017-05-26 | 2018-05-25 | Склади у фіксованих дозах |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180338922A1 (https=) |
| EP (1) | EP3630070A1 (https=) |
| JP (3) | JP7187488B2 (https=) |
| KR (3) | KR20250109242A (https=) |
| CN (1) | CN110996914A (https=) |
| AU (2) | AU2018272040A1 (https=) |
| BR (1) | BR112019024747A2 (https=) |
| CA (1) | CA3064895A1 (https=) |
| CL (1) | CL2019003437A1 (https=) |
| IL (2) | IL270866B2 (https=) |
| MX (2) | MX2019014122A (https=) |
| PH (1) | PH12019502782A1 (https=) |
| TW (1) | TWI798228B (https=) |
| UA (1) | UA126451C2 (https=) |
| WO (1) | WO2018218147A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3267989A4 (en) | 2015-03-13 | 2018-11-07 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| AU2019221765A1 (en) * | 2018-02-16 | 2020-09-10 | Esperion Therapeutics, Inc. | Sustained release formulations of bempedoic acid |
| US20210322375A1 (en) * | 2018-08-27 | 2021-10-21 | Esperion Therapeutics, Inc. | Combination drug formulations for treating patients with cardiovascular disease and associated conditions |
| EP3666750A1 (en) * | 2018-12-10 | 2020-06-17 | Sandoz AG | Crystalline form of bempedoic acid |
| WO2020213010A1 (en) * | 2019-04-16 | 2020-10-22 | Celagenex Research (India) Pvt. Ltd. | Synergistic lipid controlling compositions |
| MX2021015936A (es) | 2019-06-21 | 2022-04-26 | Esperion Therapeutics Inc | Metodos para preparar acido bempedoico y composiciones del mismo. |
| US12528759B2 (en) | 2019-10-03 | 2026-01-20 | Synthon B.V. | Crystalline forms of bempedoic acid |
| US12516013B2 (en) | 2019-12-06 | 2026-01-06 | Synthon B.V. | Crystalline forms of sodium salt of Bempedoic acid |
| CN115379861A (zh) * | 2020-04-10 | 2022-11-22 | 日本瓦姆&珀巴尔株式会社 | 缓释性主剂 |
| WO2021220236A1 (en) * | 2020-05-01 | 2021-11-04 | Cadila Healthcare Limited | Pharmaceutical compositions for combination therapy |
| CN111559961A (zh) * | 2020-05-26 | 2020-08-21 | 杭州科巢生物科技有限公司 | 一种贝派地酸晶型及其制备方法 |
| WO2021255180A1 (en) | 2020-06-19 | 2021-12-23 | Synthon B.V. | Salts of bempedoic acid |
| US20250134841A1 (en) | 2021-09-13 | 2025-05-01 | Synthon B.V. | Pharmaceutical composition of bempedoic acid |
| CA3256768A1 (en) | 2022-05-09 | 2023-11-16 | Renata Pharmaceutical (Ireland) Ltd | PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID |
| JP2024116544A (ja) * | 2023-02-16 | 2024-08-28 | 株式会社三共 | 遊技機 |
| JP2024116545A (ja) * | 2023-02-16 | 2024-08-28 | 株式会社三共 | 遊技機 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| HU230253B1 (hu) | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| JP4438268B2 (ja) | 2001-03-07 | 2010-03-24 | 大日本住友製薬株式会社 | 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤 |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| ES2625429T3 (es) | 2003-01-23 | 2017-07-19 | Esperion Therapeutics Inc. | Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes |
| AU2009292615B2 (en) * | 2008-09-17 | 2015-12-03 | Mylan Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
| JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
| ES2382773T3 (es) * | 2009-03-13 | 2012-06-13 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Composiciones de ezetimiba |
| CA2755274C (en) * | 2009-03-13 | 2017-02-28 | Sahoe Kakuda | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
| PT2459175T (pt) * | 2009-07-28 | 2018-02-07 | Egyt Gyogyszervegyeszeti Gyar | Novo processo de granulação e o granulado assim preparado |
| CN101926756B (zh) * | 2010-08-12 | 2012-01-18 | 北京赛科药业有限责任公司 | 一种氯吡格雷或其药学上可接受盐的固体制剂 |
| AR083417A1 (es) * | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| AR086675A1 (es) * | 2011-06-14 | 2014-01-15 | Merck Sharp & Dohme | Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina |
| CA2845228C (en) * | 2011-08-16 | 2021-08-10 | Baker Idi Heart & Diabetes Institute Holdings Limited | Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds |
| MX378845B (es) * | 2014-01-21 | 2025-03-10 | Bpsi Holdings Llc | Revestimientos de pelicula de liberacion inmediata que contienen gliceridos de cadena media y sustratos revestidos con los mismos. |
| EP3267989A4 (en) | 2015-03-13 | 2018-11-07 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| WO2017023165A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
| HK1257929A1 (zh) * | 2015-11-06 | 2019-11-01 | Gemphire Therapeutics Inc. | 治疗混合性血脂异常 |
-
2017
- 2017-12-29 US US15/859,279 patent/US20180338922A1/en not_active Abandoned
-
2018
- 2018-05-25 PH PH1/2019/502782A patent/PH12019502782A1/en unknown
- 2018-05-25 BR BR112019024747-5A patent/BR112019024747A2/pt unknown
- 2018-05-25 MX MX2019014122A patent/MX2019014122A/es unknown
- 2018-05-25 AU AU2018272040A patent/AU2018272040A1/en not_active Abandoned
- 2018-05-25 EP EP18731684.9A patent/EP3630070A1/en active Pending
- 2018-05-25 KR KR1020257022127A patent/KR20250109242A/ko active Pending
- 2018-05-25 IL IL270866A patent/IL270866B2/en unknown
- 2018-05-25 CA CA3064895A patent/CA3064895A1/en active Pending
- 2018-05-25 IL IL318957A patent/IL318957A/en unknown
- 2018-05-25 WO PCT/US2018/034646 patent/WO2018218147A1/en not_active Ceased
- 2018-05-25 KR KR1020197038244A patent/KR102698987B1/ko active Active
- 2018-05-25 TW TW107118013A patent/TWI798228B/zh active
- 2018-05-25 UA UAA201911462A patent/UA126451C2/uk unknown
- 2018-05-25 CN CN201880049937.4A patent/CN110996914A/zh active Pending
- 2018-05-25 JP JP2019565302A patent/JP7187488B2/ja active Active
- 2018-05-25 KR KR1020247028001A patent/KR102830720B1/ko active Active
-
2019
- 2019-11-25 CL CL2019003437A patent/CL2019003437A1/es unknown
- 2019-11-26 MX MX2023006541A patent/MX2023006541A/es unknown
-
2022
- 2022-04-14 US US17/720,625 patent/US20220249380A1/en active Pending
- 2022-11-30 JP JP2022191728A patent/JP7561814B2/ja active Active
-
2024
- 2024-06-26 AU AU2024204369A patent/AU2024204369B2/en active Active
- 2024-09-24 JP JP2024164776A patent/JP2024178341A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA126451C2 (uk) | Склади у фіксованих дозах | |
| Alhasani et al. | Self-nanoemulsifying ramipril tablets: A novel delivery system for the enhancement of drug dissolution and stability | |
| Jacques et al. | Tablet scoring: current practice, fundamentals, and knowledge gaps | |
| Alshetaili et al. | Development and characterization of sustained-released donepezil hydrochloride solid dispersions using hot melt extrusion technology | |
| Jammula et al. | Design and characterization of cefuroxime axetil biphasic floating minitablets | |
| Elezaj et al. | Pharmaceutical development of film-coated mini-tablets with losartan potassium for epidermolysis bullosa | |
| CN101528237A (zh) | 艾夫他滨药物组合物 | |
| Ancuceanu et al. | An inventory of medicinal products causing skin rash: Clinical and regulatory lessons | |
| Ibrahim et al. | Optimization and evaluation of lyophilized fenofibrate nanoparticles with enhanced oral bioavailability and efficacy | |
| Mudie et al. | Amorphous solid dispersion tablets overcome acalabrutinib ph effect in dogs | |
| Vidiyala et al. | High drug loading of amorphous solid dispersion by hot melt extrusion: The role of magnesium aluminometasilicate (neusilin® us2) | |
| Serra et al. | Dissolution efficiency and bioequivalence study using urine data from healthy volunteers: a comparison between two tablet formulations of cephalexin | |
| Kolter et al. | Development of new excipients | |
| Yun et al. | Enhanced Stability and Compatibility of Montelukast and Levocetirizine in a Fixed-Dose Combination Monolayer Tablet | |
| RU2810163C2 (ru) | Составы в фиксированных дозах | |
| TWI921644B (zh) | 固定劑量調配物 | |
| Khan et al. | Virtual clinical trials guided design of an age-appropriate formulation and dosing strategy of nifedipine for paediatric use | |
| US20250345319A1 (en) | Anticancer Compositions | |
| WO2010101485A2 (en) | A pharmaceutical composition containing celecoxib and a process of the manufacture thereof | |
| HK40020442A (en) | Fixed dose formulations | |
| CN109172578B (zh) | 磷酸哌喹在制备治疗脂类代谢紊乱和高血脂症药物中的应用 | |
| Heikal et al. | Rational Design and Efficacy Evaluation of a Novel Solid Dispersion-Based Bempedoic Acid–Ezetimibe Fixed-Dose Combination Tablet Versus Nexlizet® | |
| Patel | Design, in vitro evaluation and in vivo studies of novel delayed release tablets of pantoprazole | |
| Ravishankar | PHARAMACEUTICAL BIOTECHNOLOGY | |
| HANDLING | FORMULATIONS |